Asia Pacific Insomnia Companies
The Asia-Pacific insomnia market is quite diverse, encompassing companies with various approaches to tackling this widespread issue.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Â
Latest Asia Pacific Insomnia Companies Update
Japanese pharmaceutical company Eisai announced in October 2023 that it has received approval in China for its insomnia drug Dayvona (lemborexant). This is a significant development as China is the largest market for insomnia treatments in the Asia Pacific region.
Indian sleep tech startup Hush has raised $10 million in a Series A funding round in January 2024. The company plans to use the funds to expand its sleep apnea and insomnia management platform across Asia.
Australian digital therapeutics company Sleep Health has partnered with Bupa Global to offer its sleep program to Bupa's members in Asia. This partnership will provide access to evidence-based sleep management tools to a wider population in the region.
List of Asia Pacific Insomnia Key Companies in the Market
- Takeda Pharmaceutical Company (Japan)
- Pfizer Inc. (US)
- Eisai
- (Japan)
- Merck & Co Inc (US)
- Sanofi (France)
- GlaxoSmithKline Plc. (UK)
- Meda Consumer Healthcare Inc (US)
- Care Fusion Corporation (US)
- Pernix Therapeutics (US)
- Purdue Pharma L.P. (US)
- Consumer Healthcare Inc. (Canada)
- Dainippon Sumitomo (Japan)
- ECR Pharmaceuticals (US)
- Johnson & Johnson (US)
- Astellas (UK)
- Biocodex S A (France)
- Neurim (Switzerland)
- Flynn Pharma (UK)
Asia Pacific Insomnia Market Highlights:
Asia Pacific Insomnia Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
